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Abstract
Although smallpox was eradicated over 30 years ago, the disease remains a major threat. High mortality, high infectivity 
and low resistance of the contemporary population make the smallpox virus very attractive to terrorists. The possible 
presence of illegal stocks of the virus or risk of deliberate genetic modifications cause serious concerns among experts. 
Hence, it is reasonable to seek effective drugs that could be used in case of smallpox outbreak. This paper reviews studies on 
compounds with proven in vitro or in vivo antipoxviruses potential, which show various mechanisms of action. Nucleoside 
analogues, such as cidofovir, can inhibit virus replication. Cidofovir derivatives are developed to improve the bioavailability 
of the drug. Among the nucleoside analogues under current investigation are: ANO (adenozine N1-oxide) and its derivatives, 
N-methanocarbothymidine [(N)-MCT], or derivatitives of aciklovir, peninclovir and brivudin. Recently, ST-246 – which 
effectively inhibits infection by limiting release of progeny virions – has become an object of attention. It has been also 
been demonstrated that compounds such as: nigericin, aptamers and peptides may have antiviral potential. An interesting 
strategy to fight infections was presented in experiments aimed at defining the role of individual genes (E3L, K3L or C6L) 
in the pathogenesis, and looking for their potential blockers. Additionally, among substances considered to be effective 
in the treatment of smallpox cases, there are factors that can block viral inhibitors of the human complement system, 
epidermal growth factor inhibitors or immunomodulators. Further studies on compounds with activity against poxviruses 
are necessary in order to broaden the pool of available means that could be used in the case of a new outbreak of smallpox.
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IntroductIon
The smallpox virus (VARV – variola virus) is dsDNA virus 
belonging to the Poxviridae family, genus Orthopoxvirus. This 
genus also contains other viruses: vaccinia virus (VACV), 
cowpox (CPXV), monkeypox (MPXV), camelpox (CMLV) 
and ectromelia virus (ECTV) [1, 2]. Humans are susceptible 
to the viruses: variola, vaccina, cowpox and monkeypox [3, 4].
Among all known infectious diseases, smallpox caused 
the greatest number of deaths worldwide [3]. The disease has 
two main forms: variola major, with mortality rate reaching 
30%, and variola minor, with mortality rate below 5% [1, 3, 5]. 
Variola virus can spread by respiratory droplets or by direct 
contact. Smallpox is a disease characteristic of humans. There 
has been no reports on any animal or insect species that 
would serve as reservoirs or vectors of the virus [3].
In the past, vaccination was the basic method of 
prevention and control of smallpox. A mass vaccination 
campaign conducted under the auspices of the World Health 
Organization (WHO) in 1967-1977 made the world free 
of the disease. Eradication of smallpox was announced in 
1980, abolishing the need for further vaccination [1]. The 
majority of existing smallpox virus stocks were destroyed, 
leaving the remainder only in the possession of two WHO 
laboratories: Centers for Disease Control and Prevention in 
Atlanta (USA) and (after a transfer in 1994) the Russian State 
Research Center of Virology and Biotechnology (the Vector 
Institute) in Novosibirsk [4, 5, 6].
The cessation of immunization has resulted in lack of 
immunity to smallpox virus in the present population. 
This situation raises concerns regarding the possibility of 
purposeful use of smallpox virus as a biological weapon in 
bioterrorist attacks [6, 7]. It is suspected that there are still 
illegal stocks of the virus that could be used in the studies 
on its genetic modifications, which could potentially lead to 
dangerous infections, even in vaccinated individuals [5, 6, 7].
In Poland, the last cases of smallpox occurred in Wrocław, 
Silesia, in 1963, when the disease was diagnosed in 99 people, 
causing the death of 7 patients. Extensive means of security, 
such as mass vaccination and restrictions on transport 
of people, were undertaken to prevent the spread of the 
epidemic [8].
In the USA in 2003, a small epidemic of monkeypox broke 
out, a disease that may be fatal to humans. This event has 
shown that monkeypox virus or other animal poxviruses 
are able to break the species barrier and become a human 
pathogen [4, 9].
Since none of the anti-smallpox vaccines are regarded 
entirely safe, seeking new antiviral agents that could protect 
people in the case of a natural outbreak of epidemic, or 
deliberate use of smallpox virus, becomes a priority. A pool of 
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drugs with various mechanisms of action may be crucial for 
the rapid and effective response of a national health service 
in case of the emergence of drug-resistant or genetically-
modified virus strains [5, 7].
In smallpox, symptomatic treatment was usually used, 
and in the case of secondary bacterial infections, antibiotics 
were administrated. The smallpox vaccine used in the past 
belongs to the most dangerous vaccines because of the high 
probability of severe complications [6, 9, 10]. Symptoms such 
as eczema on vaccinated skin, systemic vaccinia, gangrenous 
vaccinia or postvaccinal encephalitis have been reported.
Cidofovir and other nucleoside analogues. For years, great 
importance in combating viral infections has been attributed 
to nucleoside analogues that can impair viral replication 
[5, 11]. In 2001, the US Food and Drug Administration (FDA) 
approved the use of cidofovir (HPMPC – (S)-1-(3-hydroxy-
2-phosphonylmethoxypropyl)cytosine) in the case of a 
smallpox outbreak [7, 12, 13]. The anti-smallpox activity of 
cidofovir in humans has not been fully described because the 
drug appeared after eradication of the disease. However, its 
effectiveness has been demonstrated in poxvirus infection in 
mice after intravenous, subcutaneous, topical, intranasal (as 
spray) and oral (as lipid prodrug) administration [14]. It has 
been confirmed that it is effective against vaccinia, cowpox, 
monkeypox, moluscum contagiosum and ecthyma. Cidofovir 
can be administered to people by the intravenous injection 
of an aqueous solution, but changing the formulation also 
allowed the use of the drug topically in the form of gels or 
creams, as well as in the form of an aerosol for inhalation 
or a lipid pro-drug (HDP-HPMPC) for oral administration 
[14, 15]. Cidofovir is officially registered as a medicine 
against CMV retinitis in patients with AIDS. It also shows 
activity against other viruses: HSV (type 1 and 2, varicella 
zoster, Epstein-Barr, and type 6, 7 and 8), polyoma, human 
papillomavirus, adenovirus, and poxvirus.
Although vaccinations are considered to be the best way 
to prevent smallpox in humans, cidofovir may be useful in 
preventing smallpox infection shortly before exposition or 
in the post-exposure treatment [14]. Cidofovir enters cells 
in the process of endocytosis and is then converted to its 
monophosphate (HPMPCp) and diphosphate (HPMPCpp) 
forms (half-life time 17-65 h), which compete with dCTP 
(deoxycytidyne triphosphate), a substrate of viral DNA 
polymerase. Inside the cells, it also forms a complex with 
choline (HPMPCp-choline, half-life time 87 h), which serves 
as a reservoir of cidofovir and promotes the long-lasting 
activity of the drug [14].
The usefulness of cidofovir in the treatment of poxvirus 
infections in animals has been confirmed in a study by Smee 
et al. [15], who demonstrated that intranasal infection with 
virulent strain of VACV caused pneumonia, weight loss 
and death in BALB/c mice. The researchers reported that a 
single intraperitoneal injection of cidofovir at a dose 100 or 
30 mg/kg 24 h after exposure resulted in 90-100 % protection 
of animals, compared to the placebo group. The drug at a 
dose of 10 mg/kg did not influence the course of infection. 
At a dose of 100 mg/kg, 20- and 8-fold reduction in viral 
titer in the lung and oral cavities was observed on the third 
day of infection, when average blood oxygen saturation was 
significantly higher, indicating recovery in lung function. 
A statistically significant reduction in consolidation of lung 
tissue and inhibition of weight loss were noted.
Therapeutic potential of cidofovir was also confirmed 
by Baker et al. [5]. From 24 known antiviral compounds 
they isolated eight: cidofovir (HPMPC), cyclic cidofovir 
(cHPMPC), (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)
adenine (HPMPA), ribavirin, tiazofurin, carbocyclic 
3-deazaadenosine, 3-deazaneplanocin A and DFBA (a 
derivative of adenosine N1-oxide), which inhibited in vitro 
replication of poxvirus strains VARV-BSH, VARV-YAM, 
VARV-GAR, VACV, CPXV and MPXV. The three most 
active compounds, cidofovir, cHPMPC and ribavirin, were 
also examined for the occurrence of drug resistance in 35 
strains of poxviruses from different geographical regions. 
It was shown that the tested strains have similar sensitivity 
to these drugs without showing resistance to any of them. 
Additionally, cidofovir reduced viral titer in tissues and body 
fluids of animals.
Due to the poor oral bioavailability of cidofovir, its 
toxicity to kidneys and the occurrence of resistant strains 
[13], the search for analogues lacking these defects is still 
continuing [12]. Several ester conjugates of cidofovir with 
lipids, such as hexadecylopropanediol (HDP-HPMPC) and 
octadecylethanediol (ODE-HPMPC) were tested. They were 
designed so that they resemble natural lipids absorbed in the 
small intestine. In contrast to cidofovir, these compounds 
penetrate effectively into the blood and cells, yielding a weaker 
concentration in the kidneys than HPMPC. Their availability 
after oral administration and lesser nephrotoxicity make 
them useful drugs for the treatment of smallpox [7, 14]. Smee 
et al. [16] found that HDP-HPMPC given once orally at doses 
100, 50 and 25 mg/kg protected 80-100% of animals infected 
intranasally with VACV. Lower doses (10 and 5 mg/kg) 
administered for five days protected 30% of animals. HOE961 
(diacetate ester prodrug of 2-amino-7-[(1,3-dihydroxy-
2propoxy)methyl]purine) administered orally for five days 
(100, 50 and 25 mg/kg) protected all animals, and the rate 
of recovery of the body weight depended on the drug dose. 
The obtained results indicate that oral administration of 
HDP-HPMPC or HOE961 has important therapeutic effects 
in the treatment of serious respiratory infections caused by 
poxviruses.
Keith et al. [17] studied the activity of pro-drugs of 
cidofovir (HPMPC), adefovir (PMEA), tenofovir (TDF, 
PMPA) and their cyclic and ester derivatives with regard 
to their ability to inhibit replication of VACV and CPXV. 
The most active compounds were derivatives of HPMPC 
and PMEA (while PMEA did not show activity against the 
viruses). The derivatives of tenofovir did not show greater 
activity than PMPA.
Sauerbrei et al. [18] studied in vitro (plaque assay) the activity 
of cyclic pronucleotides and acyclic nucleoside analogues, 
especially aciclovir, penciclovir, brivudin analogues, and 
phenolic polymers in the fight against VACV and CPXV 
infection. Among the chosen substances at doses non-toxic 
for Vero cells, three derivatives of aciclovir, one penciclovir 
derivative and two derivatives of brivudin appeared active. 
From 13 phenolic polymers, only a product of the oxidation 
of caffeic acid showed weak activity. Their action, however, 
was weaker in comparison with the reference compound – 
cidofovir, while their cytotoxicity was greater.
In order to find compounds with activity against 
poxviruses [6] hybridization of pyrazolon and pyrimidine 
nucleoside scaffolds were conducted, which are the basis 
of many drugs and biologically-active molecules that have 
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anti-inflammatory, antibacterial and anti-HSV properties. 
Two compounds created this way, 5-substituted pyrimidine 
nucleosides, showed activity against VACV and CPXV in 
in vitro studies.
Kane and Shuman [19] used an in vitro model to study 
the impact of ANO, i.e. adenosine N1-oxide on synthesis 
of macromolecules of vaccinia virus. They noted that both 
viral DNA replication and late viral protein synthesis were 
completely blocked after the use of the investigated drugs. 
Early viral proteins also were not synthesized in the presence 
of ANO, despite the viral mRNA synthesis.
Khandazhinskaya et al. [20] studied ANO derivatives, 
such as N1-alkoxy and N6-alkyl, as well as analogues having 
a trihydroxycyclopentane ring instead of ribose, for their 
activity against poxviruses. The study was conducted in 
Vero and LLC-MK2 cells, which were infected with viruses: 
VACV, CPXV, MPXV, and ECTV. The activity of the ANO 
and its derivatives depended on the type of virus and cell 
line. ECTV and MPXV appeared to be the most sensitive to 
these compounds. Modifications of ANO at position N6 did 
not cause an increase of effectiveness, and the N1-derivative 
also had activity comparable to the original compound. 
Both derivatives, however, were significantly less cytotoxic.
Smee et al. [21] studied the effectiveness of N-methano-
carbathymidine [(N)-MCT] in the treatment of infections 
caused by two strains of vaccinia virus – WR and IHD. (N)-
MCT is a carbocyclic analogue of thymidine, which has been 
shown to inhibit replication of poxviruses in vitro and in vivo. 
Its activity in vivo was studied in comparison with cidofovir 
after oral and intraperitoneal administration. It was found 
that (N)-MCT was less toxic than cidofovir. (N)-MCT was 
effective in the treatment of infections in mice, its antiviral 
activity after oral and intraperitoneal administration was 
equal, but it was less effective than cidofovir in reducing viral 
titer in the lungs, oral cavity and brain of infected animals. 
Both compounds were capable of blocking the spread of 
viruses in liver and spleen. These results are promising, but it 
is advisable to investigate the action of (N)-MCT in primates, 
as it turned out that it was less active in monkey and human 
cells than in murine cells.
There are also reports describing the activity of 
cyclopentynyl nucleosides: adenine, cytosine and 5-F-cytosine 
regarding their anti-viral properties. Chu et al. [22] showed 
in an in vitro study that these compounds could effectively 
inhibit viral replication.
Non-nucleoside compounds with anti-poxvirus activity. 
Another well-characterized compound with activity against 
the vaccinia virus is a low molecular (376 Da) and non-
toxic (CC50 > 40 µM) compound ST-246 (Tecovirimat) 
[23]. Its ability to inhibit virus spread from cell-to-cell has 
been confirmed in numerous studies in vitro and in vivo 
[23, 24, 25].
Quenelle et al. [24] tested ST-246 in in vitro and in vivo 
assays for potential against CPXV, VACV and ECTV. In vitro 
studies revealed that IC50 of the compound were: 0.48 µM, 
0.05 µM and 0.07 µM, respectively. It was shown that ST-246 
was more effective than cidofovir. In vivo studies confirmed 
the efficacy of ST-246 administered once a day for 14 days to 
mice infected with CPXV, beginning from 4th hour and 72nd 
hour after infection. When the compound was administrated 
to VACV-infected mice at a dose of 100 mg/kg for five days, a 
significant reduction in mortality was observed, even when 
treatment started 24 hours after exposure. The reduction 
was also noticed in CPXV and VACV replication in the 
liver, spleen and kidneys. ST-246 administration to animals 
infected with ECTV once a day for 10 days prevented them 
from death, even when the drug was given 72 hours after 
infection, with proven absence of the virus in liver, lungs 
and spleen. The bioavailability after oral administration and 
lack of side effects give strong evidence of a great therapeutic 
potential of ST-246.
Studies have been undertaken to investigate the specific 
targets of ST-246 action. In the CPXV strain that was resistant 
to ST-246, 1-aa mutation in V061 gene was discovered. 
Correction of this mutation restored susceptibility to the 
drug, which indicates that the V061 gene is a target site 
of ST-246. V061 has its counterpart in VACV (F13L gene), 
which encodes a large envelope protein (p37) necessary for 
the release of progeny virions [23]. In vitro studies on ST-
246 revealed that it could inhibit the cytopathic effect and 
reduce 10-fold titer of released virions. Administration after 
intranasal infection with IHD-J strain of VACV protected 
mice from death. After secondary oral administration to 
animals which survived the disease it was observed that they 
were immune to intranasal infection. ST-246 also protected 
the mice infected with 40,000 × LD50 of ECTV, and the virus 
titer in organs after eight days of treatment was below the 
detection limit (10 PFU/ml), in contrast to negative control 
where virus titer remained high. Local lesions after caudal 
administration of the virus were also limited.
Inhibitors of enzymes. Silverman et al. [26] specifically 
designed their experiments to be able to isolate compounds 
that inhibit viral polymerase (E9) or affect the factors 
responsible for its processivity (A20 and D4). DNA polymerase 
of VACV demands two additional factors for effective DNA 
synthesis: A20 (putative DNA polymerase processivity factor) 
and D4 (uracil DNA glycosylase). The researchers succeeded 
in selecting a compound that inhibits DNA polymerase (NSC 
55 636), and a compound that affects its processivity (NSC 
123 526). Their activity has been demonstrated in plaque 
assay, with low toxicity. The selected compounds may have 
great therapeutic potential in cases of smallpox, due to the 
high sequence similarity between genes E9, A20 and D4 of 
VACV, and their counterparts in VARV.
Other studies have identified a compound having no 
nucleoside scaffold, which did not inhibit virus replication, 
but affected synthesis of late proteins [27]. Sequencing 
of mutants resistant to its action revealed a mutation in 
the peripheral region of a highly-conserved viral RNA 
polymerase subunit, indicating that this is the target site of 
this compound.
Thiosemicarbazones. Some potential in fighting poxvirus 
infections is attributed to long-known compounds, 
thiosemicarbazones, which have been used in the treatment 
of people exposed to VARV, and to relieve the side-effects 
of vaccination [28]. Numerous in vitro and in vivo tests 
were carried out, but no conclusive results about the actual 
effectiveness of these substances were obtained [29, 30, 31]. 
Quenelle et al. [32] tried to investigate two compounds from 
this group: isatin-β-thiosemicarbazone (IBT) and N-methyl-
isatin-β-thiosemicarbazone (marboran, methisazone) in cells 
and mice. Preparations were administered intraperitoneally 
to animals infected intranasally with VACV or CPXV, or 
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by scarification. The compounds turned out to be active in 
the treatment of VACV infection, but marboran was more 
effective. In the case of CPXV, only the highest concentration 
of marboran reduced mortality. This compound also caused 
a reduction in VACV titers in organs, but in the case of 
CPXV, such an effect was not observed. Virus titer in swabs 
from infected skin was also not decreased. Lack of explicit 
limitation of virus replication confirms speculations [33] that 
thiosemicarbazones do not affect viral DNA polymerase (like 
cidofovir does). They rather limit transcription by interacting 
with RNA polymerase [34, 35].
Nigericin. Myskiw et al. [9] examined nigericin, an 
antibiotic and ionophore (chemical compound having the 
ability to connect to biological membranes and facilitate the 
exchange of monovalent cations for protons), for antiviral 
activity. The compound proved to be a potent inhibitor of 
VACV replication in the human cell lines HeLa, A549 and 
Huh7. In spite of the fact that there is no data about the 
mechanism of nigericin action, the results should be regarded 
as extremely promising.
Peptides and peptide aptamers. It is reported that peptides 
may also have antiviral potential [11, 36]. To combat viral 
infections, Saccucci et al. [12] used aptamers specific to A20 
protein, a component of VACV replication complex. Aptamers 
are short pieces of DNA, RNA or peptides binding specifically 
to target agents, which can be aminoacids, antibiotics, peptides, 
proteins, viruses or whole cells. They are increasingly used as a 
useful tool in diagnostics and treatment [37]. The binding and 
blocking of A20 protein inside the replication complex can 
affect the synthesis of viral DNA. One of selected aptamers 
showed the ability to interfere with synthesis of viral DNA 
in cells and formation of progeny virions. These results may 
be a breakthrough in research on finding new compounds 
that inhibit the replication of VACV [12].
Altmann et al. [38] studied the activity of EB peptide 
against VACV. The peptide consists of 16-aa sequence of 
human fibroblast growth factor and an additional ‘tag’ of 
four soluble aminoacids. In vitro studies revealed that the 
activity of the peptide against vaccinia virus is associated 
with blocking virus-cell fusion and inhibition of virus 
penetration into host cells.
Imiquimod. Tarbet et al. [39] evaluated in vivo antiviral 
activity of imiquimod, an immunomodulator which helps 
to stimulate macrophages and monocytes to produce 
interferon-α and cytokines. It is used to treat genital warts 
and some forms of skin cancer: basal-cell carcinoma or 
squamous-cell carcinoma. The study was conducted on 
hairless mice with immunosuppression, which were infected 
with vaccinia virus by scarification (giving 25 ml of virus 
(2.5 × 105 PFU) on damaged skin-sites). In the first group of 
animals, damaged skin was treated with a cream containing 
1% imiquimod, in the second group a cream with 1% 
cidofovir was applied. Mortality, skin lesions and viral titer 
were assessed in tissue samples taken at various times after 
infection. It was found that mice treated with imiquimod for 
3, 4 and 5 days, and with cidofovir for 7 days lived longer by 
4.5, 5, 4, and 5 days, compared with the control group. In all 
groups of animals a significant reduction in skin lesions was 
observed. Treatment with cidofovir and imiquimod delayed 
the appearance of the virus in lungs.
Phospholipids. Perino et al. [40] examined the surface 
phospholipids from lungs, i.e. PC (phosphatidylcholine), DPPC 
(dipalmitoylphosphatidylcholine), PG (phosphatidylglycerol), 
DPPG (dipalmitoylphosphatidylglycerol) and PE 
(phosphatidylethanolamine) in terms of their impact on 
infection with poxviruses, using two VACV strains, Lister 
(VACV-List) and Western Reserve (VACV-WR) in the 
experiment. In preliminary studies on interaction between 
the viruses and phospholipids, DPPG was selected because 
of its strongest ability to associate with the viruses. Studies 
on human A549 cells demonstrated that after pre-incubation 
of VACV with SUVs (SUVs are phospholipids organized in 
small unilamellar vesicles, allowing their use in the aquatic 
environment), inhibition of infection occurred only in the 
case of DPPG-SUV (titer reduction 40% for VACV-WR 
and 45% for VACV-List). It was shown that both the pre-
incubation of virus with DPPG-SUV and pre-treatment of 
cells with DPPG-SUV inhibited the development of infection. 
The interaction between virus and DPPG-SUV relies on 
the roundup of viral particles by phospholipids, which was 
observed with the use of electron microscopy. The results 
of experiments on murine lung epithelial cells confirmed 
the ability of DPPG to inhibit infection, which encourages 
further research.
Since the mice infected intranasally with VACV-
WR pre-incubated with SUV-DPPG survived after the 
challenge with lethal dose of virus, it was suggested that 
dipalmitoylphosphatidylcholine plays an important role in 
natural protection of animals against poxviruses. Further 
research may allow the use of this strategy in the fight against 
infections with this virus group.
New directions of research on ways of fight poxvirus 
infections. The deficiency of effective antiviral drugs 
and high frequency of genetic changes occurring in the 
genomes of pathogens cause an urgent need to increase 
efforts to develop new ways to combat the most dangerous 
viral infections. Many researchers are engaged in the search 
for new molecular factors which could be targets for new 
potential pharmaceuticals. Enzymes and structural proteins 
important for virulence are agents which currently attract 
scientists’ attention..
EGFR inhibitors. EGFR is a protein receptor located on 
the surface of cells and is activated by binding of specific 
ligands (e.g. EGF – epidermal growth factor, VGF – vaccinia 
virus growth factor). The epidermal growth factor receptor 
is composed of three domains: extracellular, membrane 
and intracellular that has an activity of tyrosine kinase. 
Stimulation of EGFR leads to autophosphorylation of the 
tyrosine kinase, located in the intracellular part of the 
receptor, followed by activation of intracellular signaling 
pathways which, through the involvement of some 
transcription factors, induce the expression of genes affecting 
proliferation, adhesion, migration, differentiation and cell 
survival [41, 42]. The growth factor encoded by the vaccinia 
virus, which is similar to VARV growth factor, stimulates 
host cells via the EGFR signaling pathway (being a ligand 
for EGFR), facilitating viral replication and spread in host 
cells. Knowledge about the participation of EGFR in the 
pathogenesis of vaccinia virus provides new molecular 
targets for the design of new antiviral drugs. Langhammer 
et al. [43] studied the activity of small molecule compounds 
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PD153035, Vandetanib and Gefitinib inhibiting tyrosine 
kinase of EGFR. Gefitinib proved to be the most effective of 
these compounds. In vitro studies on epithelial cells infected 
with VACV or CPXV showed dose-dependent reduction in 
the size and number of plaques. Blocking of phosphorylation 
of EGFR resulted in abolition of signaling, and thus limited 
the spread of poxviruses.
Impact on E3L gene. The E3L gene, which is crucial for 
the pathogenesis of smallpox, has also become the object 
of many research investigations [44, 45, 46]. It is a key gene 
for resistance of VACV to interferon and it is necessary 
for replication of the virus in many hosts [45]. Expression 
of the E3L gene is observed at early stages of infection 
[45]. E3L encodes a 190-aa protein that consists of two 
domains: C-terminal dsRBD – a highly conserved domain 
that determines the resistance to IFN and is able to bind 
dsRNA, inhibiting antiviral dsRNA-dependent kinase, and 
the N-terminal Zα – a domain that binds Z-DNA.
Brandt et al. [44], in their studies on mice, attempted 
to explain whether both domains are essential for disease 
development. In their experiments they used recombinant 
VACV strains devoid of whole gene encoding protein E3 
(VVΔE3L), or sequences encoding its N- or C-end. It was 
shown that intranasal infection with wild type of virus 
resulted in 50% falls in mice and weight loss, while infection 
with VVΔE3L did not lead to the disease. It was also found that 
both domains of E3 protein are required for full development 
of symptoms in animals, although in vitro assays showed 
that Zα domain was not necessary for virus multiplication.
In order to assess neurovirulence, VVΔE3L was 
administered directly to the brain by intracranial injection. 
VACV wild type (strain WR, a highly neurovirulent strain) 
spread systemically, whereas VVΔE3L was found only in the 
respiratory system, which proves that lack of the E3L gene 
reduces infection in mice [44].
Kwon and Rich [45] investigated the role of E3L as a 
regulator of the transcription of genes related to apoptosis 
and immune response. After experiments on HeLa cells, 
they came to the conclusion that E3L inhibits apoptosis 
induced by hygromycin B, which is a consequence of Z-DNA 
binding by the Zα domain. They also found that E3L activates 
transcription of human genes IL-6, NF-AT (nuclear factor 
activating T cells), p53, and that Z-DNA binding by the 
N-terminal domain of E3L is essential for its activity. These 
results suggest that the role of E3L in the pathogenesis 
of VACV relies on the modulation of gene expression in 
host cells.
Rice et al. [46] investigated the role of E3L and K3L genes 
of vaccinia virus, as well as the functions of proteins PKR 
and RNase L, which are key elements of the mouse response 
to intratracheal infection. To determine the function of 
the genes, they exploited recombinant VACV strains with 
deletion of K3L or E3L gene VVΔK3L, VVΔE3L, and mice in 
which genes PKR and Rnase L were suppressed individually 
or simultaneously. In poxvirus infection, interaction between 
E3L and K3L genes, which regulate the expression of RNase L 
and PKR host genes, respectively, is used to prevent dsRNA-
dependent induction of interferon. Synthesized by VACV, 
dsRNA is a potent activator of two IFN-induced antiviral 
enzymes, i.e. PKR and RNase L. PKR activated by interaction 
with dsRNA is capable of inhibiting proteins in the infected 
cell. It was shown that VACV caused fatal disease in all tested 
strains of mice. Animals with a single suppressed gene, RNase 
L or PKR, were more susceptible to disease when compared 
to wild-type animals, whereas animals with a double gene 
knockout were the most susceptible to infection. Infected 
with a recombinant virus VVΔE3L, wild-type mice were 
insensitive to infection, suggesting that E3L plays a key role 
in controlling host immune response.
RNase L(-) mice did not show any symptoms of disease, 
while 20% of PKR(-) mice died. In contrast, all RNase 
L(-) PKR(-) mice died. After infection with a recombinant 
VVΔK3L strain there were no differences in the course of the 
disease in any of murine constructs, suggesting that PKR is 
not the sole target of K3L. Since the VVΔK3L strain did not 
spread from the lungs to other tissues, it is believed that the 
cause of death in this experimental model was disease of 
the respiratory system. These results suggest that K3L gene 
facilitates the spread of the viruses.
Many viruses have developed strategies to overcome host 
immune responses, e.g. poxviruses evolved mechanisms to 
minimize the effects of interferon, inactivate the complement 
system, or to prevent activation of NK cells [47]. By binding 
of dsRNA, which is synthesized in early stages of infection, 
the C-terminal domain of E3 protein prevents activation of 
cellular effector particles – PKR and Rnase L. It is likely that 
the mechanism to counteract RNA interference also belongs 
to repertoire of viral defence strategies.
Studies by Li et al. [48] on insect cells showed that expression 
of E3 protein caused disturbance in RNA interference. 
Lantermann et al. [49] attempted to clarify the influence of 
E3 on RNA interference in mammalian cells (HeLa, 293T) 
and revealed that the expression of a marker gene of VACV 
was effectively inhibited by siRNAs, independently of the 
presence of E3 protein. The authors suggest that these results, 
different from the results by Li et al. [48], may be associated 
with different cellular systems used in experiments. Attempts 
to determine the effectiveness of siRNA targeting E3L gene 
were also undertaken by Dave et al. [47]. In vitro studies 
showed that VACV replication was inhibited in 97% in HeLa 
cells and 98% in 293T cells, which suggests that a strategy 
based on silencing E3L gene expression can be an effective 
approach to fight poxvirus infections.
Impact on C6 protein. In order to identify new viral 
proteins that may be involved in inhibiting of signaling 
pathways of innate immunity, Unterholzner et al. [50] 
investigated the role of functional proteins of VACV-WR 
strain and early C6 protein, which is present in nucleus 
and cytoplasm. Analysis showed that C6 inhibited PRRS-
induced secretion of IFN β. PRRS are receptors that recognize 
viral DNA or RNA. It was also found that mutants with a 
deletion of C6L gene, or viruses mutated in a way that did 
not allow the gene to be expressed can replicate normally in 
cell culture, whereas in vivo in comparison with wild strains, 
they showed weaker virulence. C6 protein, conservative in 
most of poxviruses, is therefore an attractive target to design 
or seek new antiviral substances.
Inhibition of complement system. The pathogenesis of 
smallpox has still not been sufficiently investigated. Lack of 
advanced research techniques in the days before eradication 
of disease meant that we do not have full knowledge about 
mechanisms that contribute to the high mortality of smallpox. 
Genes, which formerly were not considered important, may 
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affect the immune system of the host and sharpen severe 
symptoms. It is possible that among them there are genes 
related to inhibition of the activity of INF, NK cells and the 
complement system [47, 51].
The complement system may be affected by particular 
viral genes that encode specific inhibitors (PICEs – poxviral 
inhibitors of complement enzymes). It is an innate immune 
mechanism that can recognize, bind and eliminate pathogens, 
and infected cells by lysis [52]. The action of complement 
system is under the control of host genes, encoding inhibitors 
of the enzymatic cascade. These genes have probably been 
‘hijacked’ by poxviruses during their evolution and have 
become a part of their genome. Liszewski et al. [53] compared 
the activity of inhibitors of the complement system originating 
from various poxviruses: SPICE – from VARV, VCP (VICE) 
– from VACV, and MOPICE – from MPXV. SPICE appeared 
to be the most effective PICE. Scientists who have been trying 
to characterize regulation of the complement system found 
the close analogy between sites of SPICE that bind membrane 
glycosaminoglycans (e.g. heparin) and binding sites present in 
host’s inhibitors. Chimerical combination of SPICE and VCP 
turned out to be 200 times more potent than VCP. L131 residue 
seems to be critical for the activity of both factors. Antibodies 
that neutralize PICEs in vivo were also developed [53].
SummAry
The search for effective drugs against the smallpox 
virus is now an urgent need due to a possible use of 
the virus in bioterrorist attacks. In light of the fact that 
prophylactic vaccination ceased after eradication of 
smallpox, pharmaceuticals may be beneficial in the case 
of an emergency. The present review describes the groups 
of preparations which give the most promising antiviral 
effects in the research investigations, raising hope for their 
introduction as therapeutic agents in the near future.
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